

Seelos Therapeutics

20:53 15 May 2020

Seelos Therapeutics' trehalose gets Rare Pediatric Disease Designation (RPDD) for treatment of Sanfilippo syndrome

Seelos Therapeutics Inc (NASDAQ:SEEL) announced Friday that its drug SLS-005 (trehalose) has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Sanfilippo syndrome by the US Food and Drug Administration (FDA).

RPDD is an incentive program created under the Federal Food, Drug and Cosmetic Act and is meant to encourage the development of new therapies to prevent and treat rare pediatric diseases, the company said.

The FDA will award priority review vouchers to sponsors of drug candidates that meet those criteria, which allows a company to obtain priority review without having met the application requirements.

Shares in New York surged more than 31% to stand at \$0.98.

READ: Seelos Therapeutics shares push higher as it reveals patent news for SLS-005 drug

In April, trehalose was granted Orphan Disease Designation (ODD) for the treatment of Sanfilippo syndrome by the FDA as well. ODD allows companies developing a drug access to various incentives such as tax credits for qualified clinical testing.

The drug is being developed as a treatment for patients with Type A and B versions of Sanfilippo syndrome, a childhood disorder that triggers fatal brain damage.

Seelos is currently designing a study of trehalose in Europe after receiving feedback from the European Medicines Agency in March.

New board member

Separately, the company announced the appointment of pharmaceutical and biotechnology veteran Judith Dunn to its board of directors.

Dunn previously served various roles over eight years at Swiss multinational healthcare company F. Hoffman-La Roche AG, including vice president, global head of clinical development and principal medical group leader, neuroscience.

Before that, she worked as the executive medical director of CNS clinical development at Sepracor Inc and spent eight years in a variety of roles at Pfizer Inc.

"It's our privilege and honor to have Judy on our board as she brings a unique combination of clinical and regulatory experience from Roche and Pfizer in both Psychiatry and Neurology," CEO Raj Mehra said in a statement. "She will be an invaluable resource to Seelos."

In addition to her industry experience, Dunn has served as an entrepreneur in residence at Atlas Venture since June

Price: 1.01

Market Cap: \$53.96 m

1 Year Share Price Graph



December 2019 June 2020 December 20

Share Information

Code: SEEL

Listing: NASDAQ

52 week High Low
1.705 0.42

Sector: Pharma & Biotech

Website: seelostherapeutics.com

Company Synopsis:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.

action@proactiveinvestors.com

2018, the independent board member of Evolution Research Group since August 2018, a member of the NYC Mayor's Advisory Council on Life Sciences since December 2016 and a member of the Digital Health Breakthrough Network Advisory Board since 2017.

—Updated to include share price and information from Seelos' press release on Judith Dunn joining the company's board—

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).